II. Claim Amendments

Claims 1-20 (Cancelled without prejudice or disclaimer)

21. (Newly presented) An attenuated live parasite of the phylum Apicomplexa or the family of Trypanosomatidae, wherein said parasite comprises a ribosomal protein gene under the control of an inducible promoter.

22. (Newly presented) The attenuated live parasite according to Claim 21, wherein said parasite belongs to the Coccidia, the Piroplasmida or the Haemosporida.

23. (Newly presented)The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Eimeridiidae, Cryptosporidiidae or Sarcocystidae.

24. (Newly presented)The attenuated live parasite according to Claim 23, wherein said parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.

25. (Newly presented) The attenuated live parasite according to Claim 22, wherein said parasite belongs to the family of the Babesiidae or the Theileriidae.

26. (Newly presented)The attenuated live parasite according to Claim 25, wherein said parasite belongs to the genus Babesia or Theileria.

27. (Newly presented)The attenuated live parasite according to Claim 22, wherein said parasite belongs to the genus Plasmodium.

28. (Newly presented) The attenuated live parasite according to Claim 21, wherein said parasite belongs to the genus Trypanosoma or the genus Leishmania

29. (Newly presented)The attenuated live parasite according to Claim 21, wherein said inducible

promoter is based upon an operator site and a repressor protein capable of reversibly binding said operator site.

30. (Newly presented) The attenuated live parasite according to Claim 21, wherein said inducible promoter is inducible by antibiotics.

31. (Newly presented)The attenuated live parasite according to claim 20, wherein said inducible promoter is inducible by tetracycline or anhydrotetracyclin, or a derivative thereof.

32. (Newly presented)The attenuated live parasite according to claim 21, wherein a tetR-system is used as the inducible promoter.

33. (Newly presented)The attenuated live parasite according to Claim 1, wherein said ribosomal protein gene is the gene encoding L9, S3, plastid-S9 or S13, preferably L9, S3, plastid-S9 or S13 of *Toxoplasma gondii*.

34. (Newly presented) A vaccine for combating parasitic infection comprising the attenuated live parasite of Claim 21 and a pharmaceutically acceptable carrier.

35. (Newly presented) A method for the production of the vaccine according to Claim 34, said method comprising the mixing of a live attenuated parasite according to Claims 1 and a pharmaceutically acceptable carrier.

36. (Newly presented) A DNA-fragment encoding a tet-repressor fusion protein comprising the tet-repressor protein and a heterologous protein or a part thereof, said heterologous protein or a part thereof being fused to the N-terminal side of the tet-repressor protein, the monomeric form of said fusion protein having a molecular weight of less than 60 kD and being free of GPI-anchors, secretion/excretion signals and trans-membrane regions.

37. (Newly presented) An attenuated live parasite according to Claim 1, wherein said parasite comprises the tet-operator site and a DNA fragment encoding a tet-repressor fusion protein according to claim 36.

38. (Newly presented)An aAttenuated live parasite according to claim 37, wherein said parasite comprises two or more tet-operator sites.